


Arizona Immunization Program Office Unvaccinated Patient Guide



Modified from the Texas Children's Hospital Immunization Project 2014

Updated 4/2022 by the Arizona Department of Health Services

Instructions for Use
Last Reviewed and Updated April 2022

These tables were designed to serve as a quick reference for providers to use when they encounter a previously unvaccinated child whom they would like to begin on the recommended catch-up schedule for vaccination. These tables were developed using an interpretation of the recommendations found in Table 2 of the CDC’s “Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More Than 1 Month Behind”, United States 2022. The minimum ages and intervals information was taken from the CDC’s Epidemiology and Prevention of Vaccine-Preventable Diseases, 14th Edition (2021), a.k.a. The Pink Book. Providers should apply their best medical judgement in using these tables.

Please refer to the latest CDC recommendations and other reputable sources for additional guidance. Please refer to the following links prior to administering vaccines to verify recommendations regarding minimum ages and minimum intervals:

Catch-Up Immunization Schedule:

<https://www.cdc.gov/vaccines/schedules/hcp/imz/catchup.html>

Minimum Ages and Intervals (Pink Book – Appendix A):

<https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/A/age-interval-table.pdf>

CDC Recommended Immunization Schedule for Child and Adolescents:

<https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf>

Vaccine name and abbreviations:

Diphtheria-tetanus-acellular pertussis (DTaP)

Tetanus-diphtheria (Td)

Tetanus-diphtheria-acellular pertussis (Tdap)

Polio (IPV)

Pneumococcal conjugate 13-valent (PCV13)

Human Papilloma Virus (HPV)

Haemophilus influenzae type b (Hib)

Measles-Mumps-Rubella (MMR)

Measles-Mumps-Rubella-Varicella (MMRV)

Unvaccinated Patient 7 through 11 months

1st Visit 1st Dose	2nd Visit 4 weeks later	3rd Visit 4 weeks later	Due Next	Due Next
DTaP	DTaP	DTaP		DTaP Administer 4th dose at least 6 months after the 3rd dose
IPV	IPV	IPV		
Hepatitis B	Hepatitis B		Hepatitis B Administer 3rd dose at least 8 weeks after the 2nd dose and at least 16 weeks after the 1st dose	
Hib	Hib		Hib Administer 3rd dose at least 8 weeks after the 2nd dose and on or after 1 year of age	
PCV13	PCV13		PCV13 Administer 3rd dose at least 8 weeks after the 2nd dose and on or after 1 year of age	
				MMR Administer 1st dose on or after 1 year of age
				Varicella Administer 1st dose on or after 1 year of age
				Hepatitis A Administer 1st dose on or after 1 year of age
Influenza	Influenza			

Notes:

Pentacel (DTaP-IPV-Hib) may be used for the 3-dose primary series through 4 years of age. It may be used as a booster dose prior to 5 years of age.
 Pediarix (DTaP-IPV-HepB) may be used for the first 3 doses of the DTaP series through 6 years of age.
 Vaxelis (DTaP-IPV-HepB-Hib) may be used for the first 3 doses of the primary series through 4 years of age, but it is **not** for use as a booster dose.
 Combination vaccines may be used when any component is indicated and the minimum interval for each component has been met.

Unvaccinated Patient 12 through 14 months

1st Visit 1st Dose	2nd Visit 4 weeks later	3rd Visit 4 weeks later	Due Next	Due Next
DTaP	DTaP	DTaP		DTaP Administer 4th dose at least 6 months after the 3rd dose
IPV	IPV	IPV		
Hepatitis B	Hepatitis B		Hepatitis B Administer 3rd dose at least 8 weeks after the 2nd dose and at least 16 weeks after the 1st dose	
Hib		Hib Administer 2nd dose at least 8 weeks after the 1st dose		
PCV13		PCV13 Administer 2nd dose at least 8 weeks after the 1st dose		
MMR				
Varicella				
Hepatitis A				Hepatitis A Administer 2nd dose at least 6 months after the 1st dose
Influenza	Influenza			

Notes:

Pentacel (DTaP-IPV-Hib) may be used for the 3-dose primary series through 4 years of age. It may be used as a booster dose prior to 5 years of age.
 Pediarix (DTaP-IPV-HepB) may be used for the first 3 doses of the DTaP series through 6 years of age.
 Vaxelis (DTaP-IPV-HepB-Hib) may be used for the first 3 doses of the primary series through 4 years of age, but it is **not** for use as a booster dose.
 ProQuad (MMRV) may be used as early as 12 months of age, but per CDC it is **not** preferred for use as the first dose prior to 4 years of age if separate MMR and varicella vaccines are available.
 Combination vaccines may be used when any component is indicated and the minimum interval for each component has been met.

Unvaccinated Patient 15 through 23 months

1st Visit 1st Dose	2nd Visit 4 weeks later	3rd Visit 4 weeks later	Due Next	Due Next
DTaP	DTaP	DTaP		DTaP Administer 4th dose at least 6 months after the 3rd dose
IPV	IPV	IPV		
Hepatitis B	Hepatitis B		Hepatitis B Administer 3rd dose at least 8 weeks after the 2nd dose and at least 16 weeks after the 1st dose	
Hib				
PCV13		PCV13 Administer 2nd dose at least 8 weeks after the 1st dose		
MMR				
Varicella				
Hepatitis A				Hepatitis A Administer 2nd dose at least 6 months after the 1st dose
Influenza	Influenza			

Notes:

Pentacel (DTaP-IPV-Hib) may be used for the 3-dose primary series through 4 years of age. It may be used as a booster dose prior to 5 years of age.
 Pediarix (DTaP-IPV-HepB) may be used for the first 3 doses of the DTaP series through 6 years of age.
 Vaxelis (DTaP-IPV-HepB-Hib) may be used for the first 3 doses of the primary series through 4 years of age, but it is **not** for use as a booster dose.
 ProQuad (MMRV) may be used as early as 12 months of age, but per CDC it is **not** preferred for use as the first dose prior to 4 years of age if separate MMR and varicella vaccines are available.
 Combination vaccines may be used when any component is indicated and the minimum interval for each component has been met.

Unvaccinated Patient 2 through 3 years

1st Visit 1st Dose	2nd Visit 4 weeks later	3rd Visit 4 weeks later	Due Next	Due Next
DTaP	DTaP	DTaP		DTaP Administer 4th dose at least 6 months after the 3rd dose
IPV	IPV	IPV		
Hepatitis B	Hepatitis B		Hepatitis B Administer 3rd dose at least 8 weeks after the 2nd dose and at least 16 weeks after the 1st dose	
Hib				
PCV13				
MMR				
Varicella				
Hepatitis A				Hepatitis A Administer 2nd dose at least 6 months after the 1st dose
Influenza	Influenza			

Notes:

Pentacel (DTaP-IPV-Hib) may be used for the 3-dose primary series through 4 years of age. It may be used as a booster dose prior to 5 years of age.
 Pediarix (DTaP-IPV-HepB) may be used for the first 3 doses of the DTaP series through 6 years of age.
 Vaxelis (DTaP-IPV-HepB-Hib) may be used for the first 3 doses of the primary series through 4 years of age, but it is **not** for use as a booster dose.
 ProQuad (MMRV) may be used as early as 12 months of age, but per CDC it is **not** preferred for use as the first dose prior to 4 years of age if separate MMR and varicella vaccines are available.
 Combination vaccines may be used when any component is indicated and the minimum interval for each component has been met.

Unvaccinated Patient

4 years

1st Visit 1st Dose	2nd Visit 4 weeks later	3rd Visit 4 weeks later	Due Next	Due Next
DTaP	DTaP	DTaP		DTaP Administer 4th dose at least 6 months after the 3rd dose
IPV	IPV			IPV Administer 3 rd /last at least 6 months after the 2nd dose
Hepatitis B	Hepatitis B		Hepatitis B Administer 3rd dose at least 8 weeks after the 2nd dose and at least 16 weeks after the 1st dose	
Hib				
PCV13				
MMR	MMR			
Varicella			Varicella Administer 2nd dose at least 12 weeks after the 1st dose	
Hepatitis A				Hepatitis A Administer 2nd dose at least 6 months after the 1st dose
Influenza	Influenza			

Notes:

Pentacel (DTaP-IPV-Hib) may be used for the 3-dose primary series through 4 years of age. It may be used as a booster dose prior to 5 years of age.
 Pediarix (DTaP-IPV-HepB) may be used for the first 3 doses of the DTaP series through 6 years of age.
 Vaxelis (DTaP-IPV-HepB-Hib) may be used for the first 3 doses of the primary series through 4 years of age, but it is not for use as a booster dose.
 ProQuad (MMRV) is recommended for use in patients through 12 years of age and is preferred for patients 4-12 years of age. The minimum interval between 2 doses of varicella vaccine is 12 weeks.
 Kinrix (DTaP-IPV) or Quadracel (DTaP-IPV) may be used as the 5th dose of DTaP and the 4th dose of polio for children between 4 through 6 years of age.

Unvaccinated Patient 5 through 6 years

1st Visit 1 st Dose	2nd Visit 4 weeks later	3rd Visit 4 weeks later	Due Next	Due Next
DTaP	DTaP	DTaP		DTaP Administer 4th dose at least 6 months after the 3rd dose
IPV	IPV			IPV Administer 3 rd /last dose at least 6 months after the 2nd dose
Hepatitis B	Hepatitis B		Hepatitis B Administer 3rd dose at least 8 weeks after the 2nd dose and at least 16 weeks after the 1st dose	
MMR	MMR			
Varicella			Varicella Administer 2nd dose at least 12 weeks after the 1st dose	
Hepatitis A				Hepatitis A Administer 2nd dose at least 6 months after the 1st dose
Influenza	Influenza			

Notes:

Pediarix (DTaP-IPV-HepB) may be used for the first 3 doses of the DTaP series through 6 years of age.
 ProQuad (MMRV) is recommended for use in patients through 12 years of age and is preferred for patients 4-12 years of age. The minimum interval between 2 doses of varicella vaccine is 12 weeks.
 Kinrix (DTaP-IPV) or Quadracel (DTaP-IPV) may be used as the 5th dose of DTaP and the 4th dose of polio for children between 4 through 6 years of age.

Unvaccinated Patient 7 through 10 years

1st Visit 1 st Dose	2nd Visit 4 weeks later	Due Next	Due Next	Due Next
Tdap	Td/Tdap			Td/Tdap Administer 3rd dose at least 6 months after the 2nd dose
IPV	IPV			IPV Administer 3 rd dose at least 6 months after the 2nd dose
Hepatitis B	Hepatitis B		Hepatitis B Administer 3rd dose at least 8 weeks after the 2nd dose and at least 16 weeks after the 1st dose	
MMR	MMR			
Varicella		Varicella Administer 2nd dose at least 12 weeks after the 1st dose		
Hepatitis A				Hepatitis A Administer 2nd dose at least 6 months after the 1st dose
HPV Starting at age 9 years				HPV Administer 2nd dose at least 6 months after the 1st dose
Influenza	Influenza 2 nd shot recommended if ≤8 years of age and first year receiving influenza			

Notes:

ACIP recommends persons 7 years and older who have not received the minimum 3-dose series of DTaP vaccine should receive a Tdap (preferably as the 1st dose) followed by Td vaccine. Tdap may be given instead of Td to complete the series.

ProQuad (MMRV) is recommended for use in patients through 12 years of age and is preferred for patients 4-12 years of age. The minimum interval between 2 doses of varicella is 12 weeks for patients younger than 13 years of age.

Only one dose of influenza vaccine is needed annually starting at 9 years of age.

Unvaccinated Patient 11 through 14 years

1st Visit 1 st Dose	2nd Visit 4 weeks later	Due Next	Due Next	Due Next
Tdap	Td/Tdap			Td/Tdap Administer 3rd dose at least 6 months after the 2nd dose
IPV	IPV			IPV Administer 3rd at least 6 months after the 2nd dose
Hepatitis B	Hepatitis B		Hepatitis B Administer 3rd dose at least 8 weeks after the 2nd dose and at least 16 weeks after the 1st dose	
MMR	MMR			
Varicella		Varicella Administer 2nd dose at least 12 weeks after the 1st dose*		
Hepatitis A				Hepatitis A Administer 2nd dose at least 6 months after the 1st dose
Meningococcal ACWY				Meningococcal ACWY Booster at age 16 years
HPV				HPV Administer 2nd dose at least 6 months after the 1st dose
Influenza				

Notes:

ACIP recommends persons 7 years and older who have not received the minimum 3-dose series of DTaP vaccine should receive a Tdap (preferably as the 1st dose) followed by Td vaccine. Tdap may be given instead of Td to complete the series.

ProQuad (MMRV) is recommended for use in patients **through 12 years of age** and is preferred for patients 4-12 years.

The minimum interval between 2 doses of varicella vaccine is 12 weeks for patients younger than 13 years of age, and *4 weeks for patients 13 years and older.

Unvaccinated Patient 15 through 18 years

1st Visit 1 st Dose	2nd Visit 4 weeks later	Due Next	Due Next	Due Next
Tdap	Td/Tdap			Td/Tdap Administer 3rd dose at least 6 months after the 2nd dose
IPV	IPV			IPV Administer 3rd dose at least 6 months after the 2nd dose
Hepatitis B	Hepatitis B		Hepatitis B Administer 3rd dose at least 8 weeks after the 2nd dose and at least 16 weeks after the 1st dose	
MMR	MMR			
Varicella		Varicella Administer 2nd dose no sooner than 4 weeks after the 1st dose		
Hepatitis A				Hepatitis A Administer 2nd dose at least 6 months after the 1st dose
Meningococcal ACWY				Meningococcal ACWY Administer 2nd dose at 16 years of age and at least 8 weeks after the 1st dose
				Meningococcal B (MenB) Vaccination is permissively recommended for all patients 16 through 23 years age
HPV	HPV Administer 2nd dose at least 4 weeks after the 1st dose		HPV Administer 3rd dose 12 weeks after the 2nd dose and at least 5 months after the 1st dose.	
Influenza				

Notes:

ACIP recommends persons 7 years and older who have not received the minimum 3-dose series of DTaP vaccine should receive a Tdap (preferably as the 1st dose) followed by Td vaccine. Tdap may be given instead of Td to complete the series.

A second dose of Meningococcal ACWY is not needed if the 1st dose is given at 16 years of age or later.

Bexsero is 2 doses given at least 1 month apart.

Trumenba as a 2-dose series is given at least 6 months apart. Trumenba as a 3-dose series is given at 0, 1-2, and 6 months.

Bexsero and Trumenba are not interchangeable.

